Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BAY 43-9006 inhibition of oncogenic RET mutants.
Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M. Carlomagno F, et al. Among authors: wilhelm sm. J Natl Cancer Inst. 2006 Mar 1;98(5):326-34. doi: 10.1093/jnci/djj069. J Natl Cancer Inst. 2006. PMID: 16507829
BRAF is a therapeutic target in aggressive thyroid carcinoma.
Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M. Salvatore G, et al. Among authors: wilhelm sm. Clin Cancer Res. 2006 Mar 1;12(5):1623-9. doi: 10.1158/1078-0432.CCR-05-2378. Clin Cancer Res. 2006. PMID: 16533790 Free article.
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
Auclair D, Miller D, Yatsula V, Pickett W, Carter C, Chang Y, Zhang X, Wilkie D, Burd A, Shi H, Rocks S, Gedrich R, Abriola L, Vasavada H, Lynch M, Dumas J, Trail PA, Wilhelm SM. Auclair D, et al. Among authors: wilhelm sm. Leukemia. 2007 Mar;21(3):439-45. doi: 10.1038/sj.leu.2404508. Epub 2007 Jan 4. Leukemia. 2007. PMID: 17205056
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. Wilhelm SM, et al. Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443. Cancer Res. 2004. PMID: 15466206
SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer.
Wickens P, Kluender H, Dixon J, Brennan C, Achebe F, Bacchiocchi A, Bankston D, Bierer D, Brands M, Braun D, Brown MS, Chuang CY, Dumas J, Enyedy I, Hofilena G, Hong Z, Housley T, Jones B, Khire U, Kreiman C, Kumarasinghe E, Lowinger T, Ott-Morgan R, Perkins L, Phillips B, Schoenleber R, Scott WJ, Sheeler R, Redman A, Sun X, Taylor I, Wang L, Wilhelm S, Zhang X, Zhang M, Sullivan E, Carter C, Miglarese M, Levy J. Wickens P, et al. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4378-81. doi: 10.1016/j.bmcl.2007.02.075. Epub 2007 Mar 3. Bioorg Med Chem Lett. 2007. PMID: 17574417
119 results